Related Experiment Videos
A new combination chemotherapy for resistant Hodgkin disease
JAMA
|January 3, 1977
Summary
A novel chemotherapy regimen, BVDS (bleomycin, vinblastine, doxorubicin, streptozocin), shows promise for advanced Hodgkin disease. This four-drug combination achieved a 50% response rate in MOPP-resistant cases.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Advanced Hodgkin disease often requires salvage chemotherapy for resistant or relapsed cases.
- The MOPP regimen (mechlorethamine, vincristine, procarbazine, prednisone) is a standard treatment but resistance can develop.
Purpose of the Study:
- To evaluate the efficacy of a new four-drug regimen, BVDS (bleomycin, vinblastine, doxorubicin, streptozocin), in patients with advanced Hodgkin disease resistant to MOPP.
- To determine response rates, including complete remission, for the BVDS regimen.
Main Methods:
- Ten patients with advanced Hodgkin disease resistant to MOPP received 12 cycles of the BVDS regimen.
- The BVDS regimen comprised bleomycin sulfate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and streptozocin (streptozotocin).
Main Results:
- Five out of ten (50%) patients showed a response to the BVDS regimen.
- Three out of ten (30%) patients achieved a complete remission.
Conclusions:
- The BVDS regimen is an effective alternative chemotherapy option for advanced Hodgkin disease refractory to MOPP.
- BVDS may also be beneficial for newly-diagnosed patients when used sequentially with MOPP.